Voyager Therapeutics Stock Drops 19% On Gene Therapy Program Update

(RTTNews) - Voyager Therapeutics, Inc. (VYGR) is down 19.18 percent, falling $0.89 to $4.43. The decline follows the company's decision to assess alternate payloads for its gene therapy program targeting Superoxide dismutase 1 ALS.

VYGR is currently trading at $4.29, down from the previous close of $5.32. The stock has moved between $4.37 and $5.20 in today's session. Trading volume has risen to 625,005 shares, exceeding the average volume of 418,868.

The stock is at the lower end of its 52-week range of $4.37 to $10.66, as investors react to the program's delay and strategic shift.

Recent non-human primate data indicated that the current approach may not achieve the desired profile, leading Voyager to delay its investigational new drug application for VY9323 beyond mid-2025. Despite this setback, the company reaffirmed that its cash runway extends into mid-2027.